Thursday 16 October, 2025
Objectives: Nivolumab is a monoclonal antibody restoring anti-cancer immune response by blocking binding of PD-1 receptor on T-cells to PD-L1…
Read morePoster: Drug/Disease Modelling - Oncology
Impact of resting energy expenditure on nivolumab pharmacokinetics and survival in metastatic non-small cell lung cancer patients
Thursday 16 October, 2025
Objectives: Nivolumab, an immune checkpoint inhibitor targeting PD1, is currently approved in multiple indications including non-small cell lung cancer (NSCLC)…
Read morePopulation pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies
Thursday 16 October, 2025
Introduction: Ibrutinib (Imbruvica®) is a targeted therapy used for the treatment of chronic lymphocytic leukaemia (CLL) and other B-cell malignancies….
Read moreA Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
Thursday 16 October, 2025
Objectives: In oncology drug development, tumor growth related metrics (such as, tumor size ratio or time to tumor growth) are being…
Read moreComparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody
Thursday 16 October, 2025
Background: All anti-PD1/PD-L1 monoclonal antibodies approved in immuno-oncology (IO) utilized an empirical time-varying CL population PK model to inform their…
Read moreMechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data
Thursday 16 October, 2025
Introduction: PRS-344/S095012 is a bispecific antibody-Anticalin® fusion protein (referred to as MabcalinTM protein) targeting 4-1BB (CD137) and programmed death-ligand 1…
Read moreReversing resistance to anticancer treatment supported by pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in xenograft mice
Thursday 16 October, 2025
Objectives: The development of drug combination in oncology is a key domain for answering therapeutic need. For example, combination therapy…
Read moreApplication of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia
Thursday 16 October, 2025
Objectives: The aim of this work was the development of a population pharmacokinetic-pharmacodynamic (PK/PD) model describing the dynamics of white…
Read moreModeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models
Thursday 16 October, 2025
Objectives: Achieving better antitumor efficacy by drug combination is a mainstay in oncology. However, the combination efficacy of antitumor drugs might…
Read moreA population pharmacokinetic model of methotrexate in Korean people
Thursday 16 October, 2025
Introduction: Methotrexate is a drug for treatment of cancers and autoimmune diseases. To our knowledge, several population pharmacokinetic models have been…
Read more